Arca
Skip to content
Tools
Tools

Bipolar depression

Drug research and approvals for bipolar depression: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 114 studies of bipolar depression are recruiting on ClinicalTrials.gov, and Health Canada has authorized 11 drug trials for it since 2013.

  • Recruiting worldwide: 114
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 114 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 11; search them all in Canada trials
Oct 18, 2024The candesartan adjunctive bipolar depression trial - cadet: a double-blind, randomised, placebo-controlled trialCandesartanOttawa Hospital Research InstitutePending
Mar 8, 2023Cannabidiol adjunctive therapy for acute bipolar depression: a randomized double-blind, placebo controlled trialCannabidiol (PROZ-001)Dr. Lakshmi YathamOngoing
Dec 12, 2022Feasibility of inhaled nitrous oxide (N2O) versus placebo in treatment-resistant bipolar disorderNitrous oxideSt Michaels HospitalPending
Sep 8, 2022A randomized, stratified, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of JNJ-55308942 in bipolar depressionJNJ-55308942Johnson & JohnsonClosed
Apr 22, 2022Neurobiological effects of psilocybin in treatment resistant bipolar depression: an emotional-processing fmri pilot studyPsilocybinDr. Joshua D. RosenblatOngoing
Nov 12, 2021Maintenance ketamine infusions for treatment-resistant bipolar depression: an open-label extension trialKetamineUniversity Health NetworkOngoing
May 13, 2021Neural correlates of anti-suicidal response to ketamine in treatment resistant bipolar depression (deepp-study). pilot projectKetamineCentre for Addiction and Mental HealthOngoing
Oct 15, 2020Low-dose adjunctive brexpiprazole in the treatment of bipolar i and ii depression: an open-label studyBrexpiprazoleDouglas Mental Health University InstituteOngoing
May 14, 2020Pentoxifylline for bipolar depression: a proof-of-concept feasibility studyPentoxifyllineDr. Joshua D. RosenblatPending
Jun 13, 2014A mulitsite, randomized, double-blind, placebo-controlled 12-week study evaluating the efficacy, safety, and tolerability of adjunctive infliximab for the…Remicade (infliximab)University Health NetworkPending

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.